Johnson & Johnson (JNJ) announced intent to separate its Orthopaedics business. The transaction would establish a standalone orthopaedics business, operating as DePuy Synthes. Johnson & Johnson expects that the separation would increase its top-line growth and operating margins. The company is targeting completion within 18 to 24 months.
"This transaction enables Johnson & Johnson to further strengthen its focus and investment toward higher-growth areas where we can meaningfully extend and improve patient lives," said Joaquin Duato, Chairman and CEO, Johnson & Johnson.
The company also announced that Namal Nawana has been appointed to serve as Worldwide President, DePuy Synthes, effective immediately. Nawana will lead the business through the separation process. Nawana most recently served as Executive Chairman and Founder of Sapphiros, a privately-held platform company.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.